CNBX Pharmaceuticals Inc. (CNBX)
2025-05-31 | 2024-11-30 | |||
|---|---|---|---|---|
| Revenues | - | - | ||
| Research and development expense | - | - | ||
| General and administrative expenses | 40,380 | 36,837 | ||
| Total operating expenses | 40,380 | 36,837 | ||
| Loss from operations | -40,380 | -36,837 | ||
| Capital gain (loss) | - | - | ||
| Financial income (loss) | -19,347 | 2,485 | ||
| Net loss | -59,727 | -34,352 | ||
| Profit (loss) from available for sale assets | - | - | ||
| Total comprehensive (income) loss | -59,727 | -34,352 | ||
| Earnings per share, basic | - | -0.001 | ||
| Earnings per share, diluted | - | -0.001 | ||
| Weighted average number of shares outstanding, basic | 42,597,394 | 31,111,352 | ||
| Weighted average number of shares outstanding, diluted | 42,597,394 | 31,111,352 | ||